TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Immunovia AB ( (SE:IMMNOV) ) has provided an update.
Immunovia announced the publication of the VERIFI clinical study in the journal Current Oncology, validating its PancreaSure test for early-stage pancreatic cancer detection. The study confirms PancreaSure’s high sensitivity and specificity in detecting Stage I and II pancreatic cancer, especially in high-risk individuals with pancreatic cysts, reinforcing its role in early cancer detection and strengthening Immunovia’s scientific foundation in the field.
More about Immunovia AB
Immunovia AB is a diagnostic company focused on increasing survival rates for pancreatic cancer patients through early detection. The company develops and commercializes tests to detect proteins and blood-based antibodies indicative of pancreatic cancer, collaborating with healthcare providers, experts, and advocacy groups to make these tests available to high-risk individuals. The USA is a significant market for pancreatic cancer detection, with an estimated 1.8 million high-risk individuals who could benefit from annual surveillance testing.
YTD Price Performance: -38.68%
Average Trading Volume: 9,294,562
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK166.4M
See more insights into IMMNOV stock on TipRanks’ Stock Analysis page.